For research teamsHelp me find a study
Back to all studies
CompletedNCT03055338

MK-8189 Using Risperidone for schizophrenia

This study is completed in the United States. It is testing MK-8189 Using Risperidone for schizophrenia.

SchizophreniaDrugFrom 18 Years to 50 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT03055338. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

Check the official registry

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 28 sites
  • Woodland International Research Group, LLC ( Site 0001)
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Woodland Research Northwest, LLC ( Site 0014)
    Rogers, Arkansas
    Site status: Not listed — confirm with the team
  • CITRIALS ( Site 0013)
    Bellflower, California
    Site status: Not listed — confirm with the team
  • Comprehensive Clinical Development ( Site 0049)
    Cerritos, California
    Site status: Not listed — confirm with the team
  • Collaborative Neuroscience Network, LLC ( Site 0057)
    Garden Grove, California
    Site status: Not listed — confirm with the team
  • Behavioral Research Specialists, LLC ( Site 0006)
    Glendale, California
    Site status: Not listed — confirm with the team
  • Synergy East ( Site 0003)
    Lemon Grove, California
    Site status: Not listed — confirm with the team
  • NRC Research Institute ( Site 0043)
    Orange, California
    Site status: Not listed — confirm with the team
  • CNRI - Los Angeles, LLC ( Site 0026)
    Pico Rivera, California
    Site status: Not listed — confirm with the team
  • Artemis Institute for Clinical Research ( Site 0027)
    San Diego, California
    Site status: Not listed — confirm with the team
  • Schuster Medical Research Institute ( Site 0032)
    Sherman Oaks, California
    Site status: Not listed — confirm with the team
  • Collaborative Neuroscience Network, LLC ( Site 0046)
    Torrance, California
    Site status: Not listed — confirm with the team
  • Larkin Community Hospital Behavioral Health Services ( Site 0020)
    Hollywood, Florida
    Site status: Not listed — confirm with the team
  • Clinical Research Centers of America, LLC ( Site 0038)
    Oakland Park, Florida
    Site status: Not listed — confirm with the team
  • Aspire Health Partners ( Site 0016)
    Orlando, Florida
    Site status: Not listed — confirm with the team
  • Radiant Research - Atlanta ( Site 0008)
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Atlanta Center For Medical Research ( Site 0056)
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Alexian Center for Psychiatric Research ( Site 0015)
    Hoffman Estates, Illinois
    Site status: Not listed — confirm with the team
  • Lake Charles Clinical Trials, LLC ( Site 0040)
    Lake Charles, Louisiana
    Site status: Not listed — confirm with the team
  • CBH Health, LLC ( Site 0022)
    Gaithersburg, Maryland
    Site status: Not listed — confirm with the team
  • Precise Research Centers ( Site 0018)
    Flowood, Mississippi
    Site status: Not listed — confirm with the team
  • Psych Care Consultants Research ( Site 0025)
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • St. Louis Clinical Trials, LLC ( Site 0012)
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Altea Research Institute ( Site 0017)
    Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • Radiant Research -CliniLabs ( Site 0037)
    New York, New York
    Site status: Not listed — confirm with the team
  • Midwest Clinical Research Unit ( Site 0041)
    Dayton, Ohio
    Site status: Not listed — confirm with the team
  • InSite Clinical Research ( Site 0033)
    DeSoto, Texas
    Site status: Not listed — confirm with the team
  • Pillar Clinical Research, LLC ( Site 0004)
    Richardson, Texas
    Site status: Not listed — confirm with the team
In plain English

Key information made simple

What is this study testing?

This study is testing whether the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: March 8, 2017
Recruitment status
Completed
Enrollment listed in the registry
224
Sponsor
Merck Sharp & Dohme LLC
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT03055338
Official title
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT03055338. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 50 Years. The criteria appear strict, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Merck Sharp & Dohme LLC, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.